Epidermal Growth Factor Protects Squamous Cell Carcinoma against Cisplatin-Induced Cytotoxicity through Increased Interleukin-1β Expression

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ko, Shian Chin ^a   Huang, Chi Ruei ^b   Shieh, Jiunn Min ^a   Yang, Jhen Hong ^c   Chang, Wen Chang ^d   Chen, Ben Kuen ^b,c  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR RELA;

ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE; GENE FUNCTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; INTERLEUKIN 1BETA GENE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; RNA STABILITY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION;

BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHROMONES; CISPLATIN; CYTOTOXINS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1BETA; MORPHOLINES; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SESQUITERPENES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84873258394     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055795     Document Type: Article

References (51)

1. Gabrilovich DI, Nagaraj S, (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
2. Sica A, Bronte V, (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Cli Invest 117: 1155-1166.
3. Rodríguez PC, Ochoa AC, (2008) Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 222: 180-191.
4. Weber A, Wasiliew P, Kracht M, (2010) Interleukin-1 (IL-1) Pathway. Sci Signal 3: cm1-.
5. Dinarello CA, (2005) Blocking IL-1 in systemic inflammation. J Exp Med 201: 1355-1359.
6. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, et al. (2010) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1β. J Biol Chem 285: 6477-6488.
7. Apte RN, Dvorkin T, Song X, Fima E, Krelin Y, et al. (2002) Opposing effects of IL-1α and IL-1β on malignancy patterns.Tumor cell-associated IL-1α potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness. Adv. Exp. Med. Biol pp. 277-288.
8. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, et al. (2003) Differential effects of IL-1α and IL-1β on tumorigenicity patterns and invasiveness. J Immunol 171: 6448-6456.
9. Lu J-Y, Sadri N, Schneider RJ, (2006) Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev 20: 3174-3184.
10. Doyle SL, O'Neill LAJ, (2006) Toll-like receptors: From the discovery of NFκB to new insights into transcriptional regulations in innate immunity. 72: 1102-1113.
11. Hiscott J, Marois J, Garoufalis J, D'Addario M, Roulston A, et al. (1993) Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop. Mol Cell Biol 13: 6231-6240.
12. Apte R, Dotan S, Elkabets M, White M, Reich E, et al. (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25: 387-408.
13. Noordhuis MG, Eijsink JJH, ten Hoor KA, Roossink F, Hollema H, et al. (2009) Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 15: 7389-7397.
14. Nicholson RI, Gee JMW, Harper ME, (2001) EGFR and cancer prognosis. Eur J Cancer 37, Supplement 4: 9-15.
15. Grandis JR, Tweardy DJ, (1993) Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53: 3579-3584.
16. Rubin GJ, Melhem MF, Barnes EL, Tweardy DJ, (1996) Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78: 1284-1292.
17. Salomon DS, Brandt R, Ciardiello F, Normanno N, (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232.
18. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A, (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11-31.
19. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
20. Chang K-Y, Shen M-R, Lee M-Y, Wang W-L, Su W-C, et al. (2009) Epidermal growth factor-activated aryl hydrocarbon receptor nuclear translocator/HIF-1α signal pathway up-regulates cyclooxygenase-2 gene expression associated with squamous cell carcinoma. J Biol Chem 284: 9908-9916.
21. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, et al. (2002) Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548.
22. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
23. Kerpedjieva SS, Kim DS, Barbeau DJ, Tamama K, (2012) EGFR ligands drive multipotential stromal cells to produce multiple growth factors and cytokines via early growth response-1. Stem Cells Dev Epub ahead of print.
24. Chang K-Y, Tsai S-Y, Wu C-M, Yen C-J, Chuang B-F, et al. (2011) Novel phosphoinositide 3-Kinase/mTOR dual Inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res 17: 7116-7126.
25. Abbas S, Abu-Amer Y, (2003) Dominant-negative IκB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J Biol Chem 278: 20077-20082.
26. Liu YW, Arakawa T, Yamamoto S, Chang WC, (1997) Transcriptional activation of human 12-lipoxygenase gene promoter is mediated through Sp1 consensus sites in A431 cells. Biochem J 324: 133-140.
27. Andrews NC, Faller DV, (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499.
28. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK, (2002) Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. J Biol Chem 277: 6923-6928.
29. Nakamura H, Kawakami A, Ida H, Koji T, Eguchi K, (2007) Epidermal growth factor inhibits Fas-mediated apoptosis in salivary epithelial cells of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 25: 831-837.
30. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, et al. (2002) Parthenolide, an inhibitor of the nuclear factor-κB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 61: 953-963.
31. Perkins ND, (2007) Integrating cell-signalling pathways with NF-[kappa]B and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
32. Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, et al. (2000) Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 18: 293-302.
33. Lázár-Molnár E, Hegyesi H, Tóth S, Falus A, (2000) Autocine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 12: 547-554.
34. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, et al. (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: Implications for tumor progression. Int J Oncol 23: 269-284.
35. Schumann RR, Belka C, Reuter D, Lamping N, Kirschning CJ, et al. (1998) Lipopolysaccharide activates caspase-1 (interleukin-1-converting enzyme) in cultured monocytic and endothelial cells. Blood 91: 577-584.
36. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G, (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10: 241-247.
37. Schlosser S, Gansauge F, Schnelldorfer T, Ramadani M, Schwarz A, et al. (1999) Inhibition of epidermal growth factor-induced interleukin-1β-converting enzyme expression reduces proliferation in the pancreatic carcinoma cell line AsPC-1. Cancer Res 59: 4551-4554.
38. Watkins LR, Hansen MK, Nguyen KT, Lee JE, Maier SF, (1999) Dynamic regulation of the proinflammatory cytokine, interleukin-1β: Molecular biology for non-molecular biologists. Life Sci 65: 449-481.
39. Le PT, Lazorick S, Whichard LP, Haynes BF, Singer KH, (1991) Regulation of cytokine production in the human thymus: epidermal growth factor and transforming growth factor alpha regulate mRNA levels of interleukin 1 alpha (IL-1 alpha), IL-1 beta, and IL-6 in human thymic epithelial cells at a post-transcriptional level. J Exp Med 174: 1147-1157.
40. Caamaño J, Hunter CA, (2002) NF-κB family of transcription factors: Central regulators of innate and adaptive immune functions. Clin Microbiol Rev 15: 414-429.
41. Gao H, Ward PA, (2007) STAT3 and suppressor of cytokine signaling 3: potential targets in lung inflammatory responses. Expert Opin Ther Tar 11: 869-880.
42. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, et al. (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63: 2948-2956.
43. Song X, Krelin Y, Dvorkin T, Bjorkdahl O, Segal S, et al. (2005) CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1β-secreting cells. J Immunol 175: 8200-8208.
44. Neta R, Douches S, Oppenheim JJ, (1986) Interleukin 1 is a radioprotector. J Immunol 136: 2483-2485.
45. Kondo Y, Kuo SM, Lazo JS, (1994) Interleukin-1 beta-mediated metallothionein induction and cytoprotection against cadmium and cis-diamminedichloroplatinum. J Pharmacol Exp Ther 270: 1313-1318.
46. Poppenborg H, Knüpfer MM, Galla H-J, Alexander Wolff JE, (1999) In vitro modulation of cisplatin resistance by cytokines. Cytokine 11: 689-695.
47. Cenni B, Aebi S, Nehmé A, Christen RD, (2001) Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. Cancer Chemoth Pharm 47: 397-403.
48. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, et al. (2010) Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70: 2862-2869.
49. Molina-Holgado E, Ortiz S, Molina-Holgado F, Guaza C, (2000) Induction of COX-2 and PGE2 biosynthesis by IL-1β is mediated by PKC and mitogen-activated protein kinases in murine astrocytes. Br J Pharmacol 131: 152-159.
50. JUNG Y-J, ISAACS JS, LEE S, TREPEL J, NECKERS L, (2003) IL-1ß-mediated up-regulation of HIF-1α via an NFκB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 17: 2115-2117.
51. Nakao S, Kuwano T, Tsutsumi-Miyahara C, Ueda S-i, Kimura YN, et al. (2005) Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth. J Clin Invest 115: 2979-2991.